Angiotensin converting enzyme 2 activity and human atrial fibrillation: Increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling

Europace

Volumn 19, Issue 8, 2017, Pages 1280-1287

  Walters, Tomos E ^a,b   Kalman, Jonathan M ^a,b   Patel, Sheila K ^b   Mearns, Megan ^a   Velkoska, Elena ^b   Burrell, Louise M ^b,c  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c AUSTIN HOSPITAL   (Australia)

Author keywords

ACE2 activity; Atrial fibrillation; Atrial remodeling; Fibrosis

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLECAINIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SOTALOL; WARFARIN; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG HALF LIFE; ELECTRIC POTENTIAL; ELECTROGRAPHY; ENZYME ACTIVITY; EPICARDIUM MAPPING; FEMALE; HEART LEFT ATRIUM; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PAROXYSMAL ATRIAL FIBRILLATION; PERSISTENT ATRIAL FIBRILLATION; PLASMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TISSUE DOPPLER IMAGING; TRANSTHORACIC ECHOCARDIOGRAPHY; TWO DIMENSIONAL SPECKLE TRACKING ECHOCARDIOGRAPHY; ACTION POTENTIAL; ATRIAL FIBRILLATION; BLOOD; DIAGNOSTIC IMAGING; ENZYMOLOGY; FIBROSIS; HEART ATRIUM; HEART ATRIUM REMODELING; HEART FUNCTION TEST; HEART RATE; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TERTIARY CARE CENTER; UPREGULATION;

ACTION POTENTIALS; ADULT; AGED; ATRIAL FIBRILLATION; ATRIAL REMODELING; BIOMARKERS; CASE-CONTROL STUDIES; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; FEMALE; FIBROSIS; HEART ATRIA; HEART RATE; HUMANS; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TERTIARY CARE CENTERS; UP-REGULATION;

EID: 85037743625     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euw246     Document Type: Article

References (24)

1. Willems R, Sipido KR, Holemans P, Ector H, Van deWerf F, Heidbuchel H. Different patterns of angiotensin II and atrial natriuretic peptide secretion in a sheep model of atrial fibrillation. J Cardiovasc Electrophysiol 2001;12:1387-92.
2. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003;41:2197-204.
3. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002;277:14838-43.
4. Patel SK, Velkoska E, Burrell LM. Emerging markers in cardiovascular disease: where does angiotensin-converting enzyme 2 fit in? Clin Exp Pharmacol Physiol 2013;40:551-9.
5. Epelman S, TangWHW, Chen SY, Van Lente F, Francis GS, Sen S. Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J Am Coll Cardiol 2008;52:750-4.
6. Soro-Paavonen A, Gordin D, Forsblom C, Rosengard-Barlund M, Waden J, Thorn L et al. Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications. J Hypertens 2012;30:375-83.
7. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015;16:233-70.
8. Lew RA, Warner FJ, Hanchapola I, Yarski MA, Manohar J, Burrell LM et al. Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor. Exp Physiol 2008;93:685-93.
9. Kistler PM, Sanders P, Fynn SP, Stevenson IH, Spence SJ, Vohra JK et al. Electrophysiologic and electroanatomic changes in the human atrium associated with age. J Am Coll Cardiol 2004;44:109-16.
10. Sohara H, Amitani S, Kurose M, Miyahara K. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol 1997;29:106-12.
11. Li-Saw-Hee FL, Blann AD, Gurney D, Lip GY. Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function. Eur Heart J 2001;22:1741-7.
12. Hu Y-F, Yeh H-I, Tsao H-M, Tai C-T, Lin Y-J, Chang S-L et al. Electrophysiological correlation and prognostic impact of heat shock protein 27 in atrial fibrillation. Circ Arrhythm Electrophysiol 2012;5:334-40.
13. Okumura Y, Watanabe I, Nakai T, Ohkubo K, Kofune T, Kofune M et al. Impact of biomarkers of inflammation and extracellular matrix turnover on the outcome of atrial fibrillation ablation: importance of matrix metalloproteinase-2 as a predictor of atrial fibrillation recurrence. J Cardiovasc Electrophysiol 2011;22:987-93.
14. Kim SK, Park JH, Kim JY, Choi JI, Joung B, Lee M-H et al. High plasma concentrations of transforming growth factor-b and tissue inhibitor of metalloproteinase-1: potential non-invasive predictors for electroanatomical remodeling of atrium in patients with non-valvular atrial fibrillation. Circ J 2011;75:557-64.
15. Oakes RS, Badger TJ, Kholmovski EG, Akoum N, Burgon NS, Fish EN et al. Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation 2009;119: 1758-67.
16. Tops LF, Delgado V, Bertini M, Marsan NA, Uijl Den DW, Trines SAIP et al. Left atrial strain predicts reverse remodeling after catheter ablation for atrial fibrillation. J Am Coll Cardiol 2011;57:324-31.
17. Burrell LM, Risvanis J, Kubota E, Dean RG, Macdonald PS, Lu S et al. Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J 2005;26:369-75; discussion 322-4.
18. Zulli A, Burrell LM, Buxton BF, Hare DL. ACE2 and AT4R are present in diseased human blood vessels. Eur J Histochem 2008;52:39-44.
19. Pan C-H, Lin J-L, Lai L-P, Chen C-L, Stephen Huang SK, Lin C-S. Downregulation of angiotensin converting enzyme II is associated with pacing-induced sustained atrial fibrillation. FEBS Lett 2007;581:526-34.
20. Zhou T, Wang Z, Fan J, Chen S, Tan Z, Yang H et al. Angiotensin-converting enzyme-2 overexpression improves atrial remodeling and function in a canine model of atrial fibrillation. J Am Heart Assoc 2015;4:1-9.
21. Fan J, Zou L, Cui K, Woo K, Du H, Chen S et al. Atrial overexpression of angiotensin-converting enzyme 2 improves the canine rapid atrial pacing-induced structural and electrical remodeling. Basic Res Cardiol 2015;110:499-18.
22. Ling L-H, Kistler PM, Ellims AH, Iles LM, Lee G, Hughes GL et al. Diffuse ventricular fibrosis in atrial fibrillation: noninvasive evaluation and relationships with aging and systolic dysfunction. J Am Coll Cardiol 2012;60:2402-8.
23. Ellinor PT, Low AF, Patton KK, Shea MA, MacRae CA. Discordant atrial natriuretic peptide and brain natriuretic peptide levels in lone atrial fibrillation. J Am Coll Cardiol 2005;45:82-6.
24. Zhang Y, Chen A, Song L, Li M, Chen Y, He B. Association between baseline natriuretic peptides and atrial fibrillation recurrence after catheter ablation. Int Heart J 2016;57:183-9.